高眼圧症(Ocular Hypertension)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ocular Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Ocular Hypertension – Overview 10
Pipeline Products for Ocular Hypertension – Comparative Analysis 11
Ocular Hypertension – Therapeutics under Development by Companies 12
Ocular Hypertension – Therapeutics under Investigation by Universities/Institutes 14
Ocular Hypertension – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Ocular Hypertension – Products under Development by Companies 18
Ocular Hypertension – Products under Investigation by Universities/Institutes 19
Ocular Hypertension – Companies Involved in Therapeutics Development 20
Aerie Pharmaceuticals, Inc. 20
Allergan, Inc. 21
Amakem NV 22
Asahi Kasei Pharma Corp. 23
Bausch & Lomb Incorporated 24
Can-Fite BioPharma Ltd. 25
F. Hoffmann-La Roche Ltd. 26
Inotek Pharmaceuticals Corporation 27
Merck & Co., Inc. 28
Ocular Therapeutix, Inc. 29
Ono Pharmaceutical Co., Ltd. 30
Otsuka Holdings Co., Ltd. 31
Santen Pharmaceutical Co., Ltd. 32
Sylentis S.A. 33
Ocular Hypertension – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(bimatoprost + brimonidine tartrate) – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(carteolol hydrochloride + latanoprost) – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(dorzolamide hydrochloride + latanoprost) – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(latanoprost + trabodenoson) – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(tafluprost + timolol maleate) – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AMA-0076 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AR-13324 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ATS-8535 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bamosiran – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bimatoprost SR – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CF-101 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DE-117 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dorzolamide hydrochloride nanoparticle – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
latanoprost – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
latanoprost – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
latanoprost SR – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
latanoprostene bunod – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
lomerizine – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ONO-9054 – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OPA-6566 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RO-5093151 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
tafluprost – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
trabodenoson – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
travoprost SR – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Ocular Hypertension – Recent Pipeline Updates 76
Ocular Hypertension – Dormant Projects 90
Ocular Hypertension – Discontinued Products 92
Ocular Hypertension – Product Development Milestones 94
Featured News & Press Releases 94
Jan 12, 2015: Aerie Pharmaceuticals Announces Acceleration of Expected Timeline for Reporting Efficacy Results from Phase 3 Registration Trial (“Rocket 1″) of Rhopressa 94
Nov 25, 2014: Santen Launches TAPCOM Combination Ophthalmic Solution For The Treatment Of Glaucoma And Ocular Hypertension 95
Nov 12, 2014: Ocular Therapeutix Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension 95
Oct 22, 2014: Santen Announces Positive Outcome of the European Decentralized Procedure for Approval of TAPTIQOM 96
Mar 10, 2014: Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension 97
Oct 10, 2013: Santen Announces the Launch of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension 98
Sep 20, 2013: Santen Announced Approval for TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension 99
Jun 07, 2013: Zeltia announces that subsidiary Sylentis has attained the primary endpoint of the Phase IIa clinical trial with its compound SYL040012. 99
May 03, 2013: Amakem To Present Additional Data On AMA0076 At ARVO Annual Meeting 100
Jan 18, 2013: Santen Pharma Receives Japanese Approval For Tapros Mini Ophthalmic Solution 0.0015% For Glaucoma And Ocular Hypertension Treatment 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102